
13.66 Delayed Data As of Aug 05 | ![]() Today’s Change | 9.47 Today|||52-Week Range 22.00 | -30.91% Year-to-Date |
The 9 analysts offering 12-month price forecasts for Viridian Therapeutics Inc have a median target of 32.00, with a high estimate of 40.00 and a low estimate of 25.00. The median estimate represents a +134.26% increase from the last price of 13.66.
The current consensus among 9 polled investment analysts is to Buy stock in Viridian Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.